Preclinical and translational PET/MR imaging

Journal of Nuclear Medicine

Volumn 55, Issue 6 SUPPL. 2, 2014, Pages

  Wehrl, Hans F ^a   Wiehr, Stefan ^a   Divine, Mathew R ^a   Gatidis, Sergios ^a   Gullberg, Grant T ^b,c   Maier, Florian C ^a   Rolle, Anna Maria ^a   Schwenck, Johannes ^a   Thaiss, Wolfgang M ^a   Pichler, Bernd J ^a  

^a UNIVERSITY OF TÜBINGEN   (Germany)

^b LAWRENCE BERKELEY NATIONAL LABORATORY   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Cardiology; Connectomics; Neurology; Oncology; PET MRI

Indexed keywords

3' FLUOROTHYMIDINE F 18; CHOLINE C 11; FLORBETABEN; FLUORODEOXYGLUCOSE F 18; FLUTEMETAMOL F 18; GADOLINIUM PENTETATE; PITTSBURGH COMPOUND B; RACLOPRIDE C 11; WATER O 15;

ALZHEIMER DISEASE; BOLD SIGNAL; BRAIN MAPPING; CARDIOVASCULAR MAGNETIC RESONANCE; CONNECTOME; DIFFERENTIAL DIAGNOSIS; DIFFUSION COEFFICIENT; EARLY DIAGNOSIS; ECHINOCOCCOSIS; FUNCTIONAL MAGNETIC RESONANCE IMAGING; HEART SCINTISCANNING; HUMAN; MATHEMATICAL MODEL; MOLECULAR IMAGING; NEUROIMAGING; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROSTATE CANCER; REVIEW; TUMOR MODEL; TUMOR VOLUME; TUMOR XENOGRAFT;

EID: 84903192362     PISSN: 01615505     EISSN: None     Source Type: Journal    
DOI: 10.2967/jnumed.113.129221     Document Type: Review

References (77)

1. Pysz MA, Gambhir SS, Willmann JK. Molecular imaging: current status and emerging strategies. Clin Radiol. 2010;65:500-516.
2. Judenhofer MS, Wehrl HF, Newport DF, et al. Simultaneous PET-MRI: a new approach for functional and morphological imaging. Nat Med. 2008;14:459-465. (Pubitemid 351499385)
3. Wehrl HF, Hossain M, Lankes K, et al. Simultaneous PET-MRI reveals brain function in activated and resting state on metabolic, hemodynamic and multiple temporal scales. Nat Med. 2013;19:1184-1189.
4. Wehrl HF, Judenhofer MS, Wiehr S, Pichler BJ. Pre-clinical PET/MR: technological advances and new perspectives in biomedical research. Eur J Nucl Med Mol Imaging. 2009;36(suppl 1):S56-S68.
5. Drzezga A, Souvatzoglou M, Eiber M, et al. First clinical experience with integrated whole-body PET/MR: comparison to PET/CT in patients with oncologic diagnoses. J Nucl Med. 2012;53:845-855.
6. Rischpler C, Nekolla SG, Dregely I, Schwaiger M. Hybrid PET/MR imaging of the heart: potential, initial experiences, and future prospects. J Nucl Med. 2013;54:402-415.
7. Sander CY, Hooker JM, Catana C, et al. Neurovascular coupling to D2/D3 dopamine receptor occupancy using simultaneous PET/functional MRI. Proc Natl Acad Sci USA. 2013;110:11169-11174.
8. 2O-PET and BOLD-fMRI. Neuroimage. 2014;89:271-279.
9. 11C-choline positron emission tomography. Cancer Res. 2013;73:1470-1480.
10. Dukart J, Mueller K, Horstmann A, et al. Combined evaluation of FDG-PET and MRI improves detection and differentiation of dementia. PLoS ONE. 2011;6:e18111.
11. Bailey DL, Barthel H, Beyer T, et al. Summary report of the First International Workshop on PET/MR Imaging, March 19-23, 2012, Tübingen, Germany. Mol Imaging Biol. 2013;15:361-371.
12. Maramraju SH, Smith SD, Junnarkar SS, et al. Small animal simultaneous PET/MRI: initial experiences in a 9.4 T microMRI. Phys Med Biol. 2011;56:2459-2480.
13. Ng TS, Bading JR, Park R, et al. Quantitative, simultaneous PET/MRI for intratumoral imaging with an MRI-compatible PET scanner. J Nucl Med. 2012;53:1102-1109.
14. Loi M, Di Paolo D, Becherini P, et al. The use of the orthotopic model to validate antivascular therapies for cancer. Int J Dev Biol. 2011;55:547-555.
15. Zieker D, Königsrainer I, Weinreich J, et al. Phosphoglycerate kinase 1 promoting tumor progression and metastasis in gastric cancer - detected in a tumor mouse model using positron emission tomography/magnetic resonance imaging. Cell Physiol Biochem. 2010;26:147-154.
16. Braren R, Altomonte J, Settles M, et al. Validation of preclinical multiparametric imaging for prediction of necrosis in hepatocellular carcinoma after embolization. J Hepatol. 2011;55:1034-1040.
17. Vriens D, Disselhorst JA, Oyen WJ, de Geus-Oei LF, Visser EP. Quantitative assessment of heterogeneity in tumor metabolism using FDG-PET. Int J Radiat Oncol Biol Phys. 2012;82:e725-e731.
18. 18F-FDG/PET. Magn Reson Med. 2013;69:781-792.
19. Yankeelov TE, Atuegwu NC, Deane NG, Gore JC. Modeling tumor growth and treatment response based on quantitative imaging data. Integr Biol (Camb). 2010;2:338-345.
20. Atuegwu NC, Gore JC, Yankeelov TE. The integration of quantitative multimodality imaging data into mathematical models of tumors. Phys Med Biol. 2010;55:2429-2449.
21. Anderson AW, Xie J, Pizzonia J, Bronen RA, Spencer DD, Gore JC. Effects of cell volume fraction changes on apparent diffusion in human cells. Magn Reson Imaging. 2000;18:689-695. (Pubitemid 30626358)
22. Pichler BJ, Wehrl HF, Kolb A, Judenhofer MS. Positron emission tomography/magnetic resonance imaging: the next generation of multimodality imaging? Semin Nucl Med. 2008;38:199-208. (Pubitemid 351466918)
23. 18F-fluorothymidine in a genetically engineered mouse model of high-grade gliomas. J Nucl Med. 2008;49:422-429.
24. Raylman RR, Majewski S, Lemieux SK, et al. Simultaneous MRI and PET imaging of a rat brain. Phys Med Biol. 2006;51:6371-6379. (Pubitemid 46217627)
25. Pichler BJ, Judenhofer MS, Catana C, et al. Performance test of an LSO-APD detector in a 7-T MRI scanner for simultaneous PET/MRI. J Nucl Med. 2006;47:639-647. (Pubitemid 46768465)
26. Judenhofer MS, Catana C, Swann BK, et al. PET/MR images acquired with a compact MR-compatible PET detector in a 7-T magnet. Radiology. 2007;244:807-814. (Pubitemid 47292092)
27. Pichler BJ, Judenhofer MS, Pfannenberg C. Multimodal imaging approaches: PET/CT and PET/MRI. Handb Exp Pharmacol. 2008;185:109-132.
28. Catana C, Procissi D, Wu Y, et al. Simultaneous in vivo positron emission tomography and magnetic resonance imaging. Proc Natl Acad Sci USA. 2008;105:3705-3710. (Pubitemid 351723462)
29. Imaizumi M, Yamamoto S, Kawakami M, et al. Simultaneous imaging of magnetic resonance imaging and positron emission tomography by means of MRI-compatible optic fiber-based PET: a validation study in ex vivo rat brain. Jpn J Radiol. 2009;27:252-256.
30. Büscher K, Judenhofer MS, Kuhlmann MT, et al. Isochronous assessment of cardiac metabolism and function in mice using hybrid PET/MRI. J Nucl Med. 2010;51:1277-1284.
31. Yamamoto S, Imaizumi M, Kanai Y, et al. Design and performance from an integrated PET/MRI system for small animals. Ann Nucl Med. 2010;24:89-98.
32. Pichler BJ, Kolb A, Nagele T, Schlemmer HP. PET/MRI: paving the way for the next generation of clinical multimodality imaging applications. J Nucl Med. 2010;51:333-336.
33. Wehrl HF, Sauter AW, Judenhofer MS, Pichler BJ. Combined PET/MR imaging: technology and applications. Technol Cancer Res Treat. 2010;9:5-20.
34. Uppal R, Catana C, Ay I, Benner T, Sorensen AG, Caravan P. Bimodal thrombus imaging: simultaneous PET/MR imaging with a fibrin-targeted dual PET/MR probe - feasibility study in rat model. Radiology. 2011;258:812-820.
35. Wehrl HF, Judenhofer MS, Thielscher A, Martirosian P, Schick F, Pichler BJ. Assessment of MR compatibility of a PET insert developed for simultaneous multiparametric PET/MR imaging on an animal system operating at 7 T. Magn Reson Med. 2011;65:269-279.
36. Tatsumi M, Yamamoto S, Imaizumi M, et al. Simultaneous PET/MR body imaging in rats: initial experiences with an integrated PET/MRI scanner. Ann Nucl Med. February 23, 2012 [Epub ahead of print].
37. Lee WW, Marinelli B, van der Laan AM, et al. PET/MRI of inflammation in myocardial infarction. J Am Coll Cardiol. 2012;59:153-163.
38. Majmudar MD, Nahrendorf M. Cardiovascular molecular imaging: the road ahead. J Nucl Med. 2012;53:673-676.
39. Judenhofer MS, Cherry SR. Applications for preclinical PET/MRI. Semin Nucl Med. 2013;43:19-29.
40. Nappi C, El Fakhri G. State of the art in cardiac hybrid technology: PET/MR. Curr Cardiovasc Imaging Rep. 2013;6:338-345.
41. Veress AI, Weiss JA, Huesman RH, et al. Measuring regional changes in the diastolic deformation of the left ventricle of SHR rats using microPET technology and hyperelastic warping. Ann Biomed Eng. 2008;36:1104-1117.
42. de las Fuentes L, Soto PF, Cupps BP, et al. Hypertensive left ventricular hypertrophy is associated with abnormal myocardial fatty acid metabolism and myocardial efficiency. J Nucl Cardiol. 2006;13:369-377. (Pubitemid 43792983)
43. Patlak CS, Blasberg RG, Fenstermacher JD. Graphical evaluation of blood-to-brain transfer constants from multiple-time uptake data. J Cereb Blood Flow Metab. 1983;3:1-7. (Pubitemid 13129630)
44. Hernandez AM, Huber JS, Murphy ST, et al. Longitudinal evaluation of left ventricular substrate metabolism, perfusion and dysfunction in the SHR model of hypertrophy using microPET/CT imaging. J Nucl Med. 2013;54:1938-1945.
45. Weiner MW, Veitch DP, Aisen PS, et al. The Alzheimer's Disease Neuroimaging Initiative: a review of papers published since its inception. Alzheimers Dement. 2012;8(1 suppl):S1-S68.
46. Brookmeyer R, Johnson E, Ziegler-Graham K, Arrighi HM. Forecasting the global burden of Alzheimer's disease. Alzheimers Dement. 2007;3:186-191. (Pubitemid 46825511)
47. 18F) in patients with Alzheimer's disease and healthy controls: a multicentre phase 2 diagnostic study. Lancet Neurol. 2011;10:424-435.
48. Wolk DA, Grachev ID, Buckley C, et al. Association between in vivo fluorine 18-labeled flutemetamol amyloid positron emission tomography imaging and in vivo cerebral cortical histopathology. Arch Neurol. 2011;68:1398-1403.
49. Clark CM, Schneider JA, Bedell BJ, et al. Use of florbetapir-PET for imaging beta-amyloid pathology. JAMA. 2011;305:275-283.
50. 18F-florbetapir PET agent. J Nucl Med. 2012;53(6):15N.
51. 11C-PIB across the spectrum of Alzheimer's disease. Eur J Nucl Med Mol Imaging. 2014;41:290-300.
52. 18F-florbetaben for Abeta imaging in ageing and Alzheimer's disease. Eur J Nucl Med Mol Imaging. 2012;39:983-989.
53. Villain N, Chetelat G, Grassiot B, et al. Regional dynamics of amyloid-beta deposition in healthy elderly, mild cognitive impairment and Alzheimer's disease: a voxelwise PiB-PET longitudinal study. Brain. 2012;135:2126-2139.
54. Bateman RJ, Xiong C, Benzinger TL, et al. Clinical and biomarker changes in dominantly inherited Alzheimer's disease. N Engl J Med. 2012;367:795-804.
55. Jack CR Jr, Knopman DS, Jagust WJ, et al. Hypothetical model of dynamic biomarkers of the Alzheimer's pathological cascade. Lancet Neurol. 2010;9:119-128.
56. Jack CR Jr, Knopman DS, Jagust WJ, et al. Tracking pathophysiological processes in Alzheimer's disease: an updated hypothetical model of dynamic biomarkers. Lancet Neurol. 2013;12:207-216.
57. Raichle ME, Herscovitch P, Mintun MA, Martin RW. Cerebral metabolism with positron emission tomography and 0-15 radiopharmaceuticals. Int J Neurol. 1984;18:75-78.
58. Petersen ET, Zimine I, Ho YC, Golay X. Non-invasive measurement of perfusion: a critical review of arterial spin labelling techniques. Br J Radiol. 2006;79:688-701. (Pubitemid 44283159)
59. 2 inhalation PET. J Cereb Blood Flow Metab. 2009;29:355-364.
60. 2) mapping in rat cortex: a multiparametric approach to calibration of BOLD image contrast at 7 Tesla. J Cereb Blood Flow Metab. 2000;20:847-860.
61. Gauthier CJ, Hoge RD. A generalized procedure for calibrated MRI incorporating hyperoxia and hypercapnia. Hum Brain Mapp. 2013;34:1053-1069.
62. Cumming P. PET neuroimaging: the white elephant packs his trunk? Neuroimage. 2014;84:1094-1100.
63. Fox PT, Raichle ME, Mintun MA, Dence C. Nonoxidative glucose consumption during focal physiologic neural activity. Science. 1988;241:462-464.
64. Raichle ME, MacLeod AM, Snyder AZ, Powers WJ, Gusnard DA, Shulman GL. A default mode of brain function. Proc Natl Acad Sci USA. 2001;98:676-682. (Pubitemid 32105102)
65. Biswal B, Yetkin FZ, Haughton VM, Hyde JS. Functional connectivity in the motor cortex of resting human brain using echo-planar MRI. Magn Reson Med. 1995;34:537-541.
66. Hoff GE, Van den Heuvel MP, Benders MJ, Kersbergen KJ, De Vries LS. On development of functional brain connectivity in the young brain. Front Hum Neurosci. 2013;7:650.
67. Chen G, Zhang HY, Xie C, Zhang ZJ, Teng GJ, Li SJ. Modular reorganization of brain resting state networks and its independent validation in Alzheimer's disease patients. Front Hum Neurosci. 2013;7:456.
68. Di X, Biswal BB. Metabolic brain covariant networks as revealed by FDG-PET with reference to resting-state fMRI networks. Brain Connect. 2012;2:275-283.
69. Yakushev I, Chetelat G, Fischer FU, et al. Metabolic and structural connectivity within the default mode network relates to working memory performance in young healthy adults. Neuroimage. 2013;79:184-190.
70. Zhang D, Raichle ME. Disease and the brain's dark energy. Nat Rev Neurol. 2010;6:15-28.
71. Hyder F, Rothman DL. Neuronal correlate of BOLD signal fluctuations at rest: err on the side of the baseline. Proc Natl Acad Sci USA. 2010;107:10773-10774.
72. 18F-FDG use in inflammation and infection. J Nucl Med. 2013;54:647-658.
73. 18F-FDG PET/CT in the diagnosis of occult bacterial infections in children. Eur J Pediatr. 2013;172:1111-1115.
74. Glaudemans AW, Quintero AM, Signore A. PET/MRI in infectious and inflammatory diseases: will it be a useful improvement? Eur J Nucl Med Mol Imaging. 2012;39:745-749.
75. Schlemmer HP, Pichler BJ, Schmand M, et al. Simultaneous MR/PET imaging of the human brain: feasibility study. Radiology. 2008;248:1028-1035.
76. Delso G, Furst S, Jakoby B, et al. Performance measurements of the Siemens mMR integrated whole-body PET/MR scanner. J Nucl Med. 2011;52:1914-1922.
77. Wehrl HF. Possibilities and Limitations of Combined PET/MR in Oncological and Neurological Basic Research [in German; dissertation]. Tuebingen: Eberhard Karls University Tuebingen; 2013.